ICCM News and Press, IceCure Medical Ltd. From 04/03/24

2024-04-03 10:42:06 ET More on IceCure Medical FDA agrees to review IceCure request for De Novo classification Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure Medical Financial information for IceCure Medical ...

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance PR Newswire Co...

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes PR Newswire Continuous innovation as a global leader in minimally invasive liquid-nitrogen based cryoablation systems CAESAREA, Israel , April 2, 2024 /PR...

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 PR Newswire Overview of U.S. Commercial Strategy will be Discussed on Conference Ca...

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy PR Newswire Expects to submit full dataset to ...

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes PR Newswire Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed Cryogenic flow control enhances th...

IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference PR Newswire CAESAREA, Israel , March 7, 2024 /PRNewswire/ -- ...

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 PR Newswire MRI reveals disappearance of hemorrhagic signal and development of necrotic changes Pain reduced from a median of 7 on...

Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop PR Newswire Session conducted...

Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer PR Newswire Independent study in women deemed inoperable for breast cancer reports median tumor reduction of 100% at 6 and 12 months following cryoablation ...